eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
5/2021
vol. 38
 
Share:
Send email
Share:
abstract:
Original paper

Evaluation of the relationship of IL17A and IL17F gene polymorphisms with the response to treatment in psoriatic patients using biological drugs: case-control study in patients in eastern Turkey

Hatice Uce Ozkol
1
,
Gokhan Gorgisen
2
,
Can Ates
3
,
Halil Özkol
2
,
Yasin Tülüce
2
,
Hulya Savas
4
,
İsmail Musab Gulacar
2

  1. Department of Dermatology, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey
  2. Department of Medical Biology, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey
  3. Department of Biostatistics, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey
  4. Department of Dermatology, Erzincan State Hospital, Erzincan, Turkey
Adv Dermatol Allergol 2021; XXXVIII (5): 780-787
DOI: https://doi.org/10.5114/ada.2020.95383
Online publish date: 2020/05/26
View full text Get citation
 
Introduction
IL-17A and IL-17F cytokines have important roles in the pathogenesis of psoriasis.

Aim
To examine the associations of IL-17A rs2275913 and IL-17F rs763780 variants with the development of psoriasis and whether these polymorphisms affect the responsiveness of biological agents.

Material and methods
In our case-controlled study, which included 83 psoriatic patients who were treated with different biological agents and 69 healthy controls, we genotyped IL-17A rs2275913 and IL-17F rs763780 variants using TaqMan probes.

Results
We did not observe statistically significant changes in genotype frequencies of IL-17A rs2275913 (p = 0.922) and IL-17F rs763780 (p = 0.621) variants between patient and control groups. Although we did not find any association between these polymorphisms and the development of psoriasis, statistical analyses showed that individuals with the IL-17A AA genotype had shorter disease duration (9.09 ±6.82, p = 0.020) and AA genotype frequency was higher in patients who used single conventional treatment (34.6%; p = 0.025). Another analysis also showed that 36.4% and 45.5% of patients who had less than 10-year disease duration were detected as IL-17A AA genotype (p = 0.009). For patients with PASI90 and PASI100 response, the IL-17A AA genotype was significantly higher (p = 0.015). On the other hand, we did not detect any statistically significant correlation between variants and response to biological agents.

Conclusions
According to our results, we may suggest that rs2275913 variant seems to be associated with disease duration, use of single conventional treatment and responsiveness of PASI90 and PASI100 however both variants have no effect on the susceptibility to psoriasis in the population of Eastern Turkey.

keywords:

psoriasis, IL-17A, IL-17F, secukinumab, adalimumab, ustekinumab
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.